ORPHA:2717
Oculotrichoanal syndrome
Also known as: MOTA syndrome · Manitoba oculotrichoanal syndrome · Marles syndrome · Marles-Greenberg-Persaud syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
51
46.9th percentile
Trials
0
Interventional, condition-specific
Researchers
312
Distinct authors in sample
Gene link
FREM1
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Oculotrichoanal syndrome is a form of rare, multiple anomalies/ syndrome characterized by a combination of various nose, eye, gastrointestinal and genitourinary abnormalities. Clinical presentation is variable and often includes bifid and broad nasal tip, aberrant anterior hairline, coloboma, cryptophthalmos or unilateral anophthalmia, anal anomalies, and omphalocele. Intelligence and global development is normal.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009560
- MeSH:C536022
- OMIM:248450
- UMLS:C1855425
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — FREM1
- LiteraturePresent
51 matched papers (35 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FREM1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
51
51 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
51 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
35 in the last 10 years · medium confidence · 46.9th percentile (publications denominator)
Phrase hits: 51 · MeSH hits: 0
Who's working on it?
312
Distinct author names in 51 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Li C4 papers · 2011
Genetics and Metabolism Program, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada. chumei.li@utoronto.ca
Papers in Europe PMC - 02Liu Y4 papers · 2026
Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.
Papers in Europe PMC - 03Moosajee M4 papers · 2020
UCL Institute of Ophthalmology, London EC1V 9EL, UK. m.moosajee@ucl.ac.uk.
Papers in Europe PMC - 04Slavotinek A4 papers · 2013
Department of Pediatrics, Division of Clinical Genetics, University of California, San Francisco, California 94143-0748, USA. slatovia@peds.ucsf.edu
Papers in Europe PMC - 05Chudley AE3 papers · 2011Papers in Europe PMC
- 06Hildebrandt F3 papers · 2022
Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Howard Hughes Medical Institute, Chevy Chase, Maryland friedhelm.hildebrandt@childrens.harvard.edu.
Papers in Europe PMC - 07Kiyozumi D3 papers · 2021
Research Institute for Microbial Diseases, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
Papers in Europe PMC - 08Schanze D3 papers · 2017
Institute of Human Genetics, University Hospital of Magdeburg, Magdeburg, Germany.
Papers in Europe PMC - 09
- 10Smyth I3 papers · 2013Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Oculotrichoanal syndrome" OR "MOTA syndrome" OR "Manitoba oculotrichoanal syndrome" OR "Marles syndrome" OR "Marles-Greenberg-Persaud syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Oculotrichoanal syndrome" OR "MOTA syndrome" OR "Manitoba oculotrichoanal syndrome" OR "Marles syndrome" OR "Marles-Greenberg-Persaud syndrome" OR "FREM1"
Recall-expansion terms: FREM1
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T20:56:45.347Z